What are we expecting to learn from the MPO study?

Contributions to Nephrology

Volumn 149, Issue , 2005, Pages 83-89

  Locatelli, Francesco ^a   Pozzoni, Pietro ^a   Di Filippo, Salvatore ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL MEMBRANE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EQUIPMENT DESIGN; HUMAN; INSTRUMENTATION; PERMEABILITY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT OUTCOME;

EQUIPMENT DESIGN; HUMANS; MEMBRANES, ARTIFICIAL; PERMEABILITY; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 20544444253     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000085460     Document Type: Article

References (20)

1. US Renal Data System: USRDS 2004 Annual Data Report. Bethesda, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
2. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Brugg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolf RA, Held PJ, Port FK: Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:108-120.
3. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996;50:1293-1302.
4. Locatelli F, Andrulli S, Pecchini F, Pedrini L, Agliata S, Lucchi L, Farina M, La Milia V, Grassi C, Borghi M, Redaelli B, Conte F, Ratto G, Cabiddu G, Grossi C, Modenese R: Effect of high-flux dialysis on the anemia of haemodialysis patients. Nephrol Dial Transplant 2000;15:1399-1409.
5. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D: Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi e Trapianto. Kidney Int 1999;55:286-293.
6. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-1101.
7. Schiffl H, Fischer R, Lang SM, Mangel E: Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux. Nephrol Dial Transplant 2000;16:840-845.
8. Lindsay RM, Spanner E: A hypothesis: The protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis 1989;13:382-389.
9. Wizemann V, Lotz C, Techert F, Uthoff S: On-line hemodiaf iltration versus low-flux haemodialysis: A prospective randomized study. Nephrol Dial Transplant 2000;15(suppl 1):S43-S48.
10. Hartmann J, Fricke H, Schiffl H: Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997;30:366-373.
11. Hornberger JC, Chernew M, Petersen J, Garber AM: A multi-variate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992;3:1227-1237.
12. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, Agodoa LY, Port FK: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999;33:349-355.
13. Woods HF, Nandakumar M: Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000;15(suppl 1):S36-S42.
14. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ: Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001;37:276-286.
15. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
16. Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R: The effect of membrane permeability on ESRD: Design of a prospective randomised multicentre trial. J Nephrol 1999;12:85-88.
17. Locatelli F, Marcelli D, Conte F, Del Vecchio L, Limido A, Malberti F, Spotti D, Sforzini S for the Registro Lombardo Dialisi e Trapianto: Patient selection affects end-stage renal disease outcome comparisons. Kidney Int 2000;57(suppl 74):S94-S99.
18. Locatelli F, Port FK, Pisoni RL, Martin-Malo A, Papadimitriou M, Vanholder R, Hannedouche T, Jacobson SH, Ronco C, Loureiro A, Czekalski S, Wizemann V, MPO Study Group: Patient and treatment characteristics in the MPO Study: Validation against the DOPPS population. Nephrol Dial Transplant 2003;18(suppl 4):A196.
19. Locatelli F, Hannedouche T, Jacobson SH, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R, MPO Study Group: Risk factors for cardiovascular diseases in patients starting dialysis in Northern and Southern Europe: Results from the MPO Study. Nephrol Dial Transplant 2002;17(suppl 1):A11.
20. Jager KJ, Merkus MP, Boeschoten EW, Dekker FW, Stevens P, Krediet RT: Dialysis in the Netherlands: The clinical condition of new patients put into a European perspective. NECOSAD Study Group. Netherlands Cooperative Study on the Adequacy of Dialysis. Nephrol Dial Transplant 1999;14:2438-2444.